The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, ...

PORTLAND, IA, UNITED STATES, February 13, 2025 /EINPresswire / -- LFIA based rapid test market is anticipated to exhibit growth owing to increase in incidence of infectious disease, rise in awareness ...

AliveDx seeks US FDA 510(k) premarket approval for MosaiQ AiPlex CD multiplex microarray: Eysins, Switzerland Tuesday, February 11, 2025, 12:00 Hrs [IST] AliveDx, an established c ...

The MosaiQ AiPlex CD is designed to improve the  accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows EYSINS, Switzerland , Feb.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

Acrivon Therapeutics, Inc. (ACRV) is up by 14 percent on Wednesday. The stock surged after the company announced that the U.S. Food ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

The test, which runs on the Swiss company's high-throughput MosaiQ System, detects 15 different autoantibodies.

AliveDx’s CE mark for the systematic autoimmune rheumatic disease (SARD) assay marks its fifth approval in the past 18 months ...